Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants

• Bosco Paes,
• Marcello Lanari,
• Barry Rodgers-Gray,
• John Fullarton,
• Xavier Carbonell-Estrany

Affiliations

Bosco Paes

Department of Pediatrics (Neonatal Division), McMaster University, Hamilton, ON, Canada

Marcello Lanari

Paediatric Emergency Unit, IRCCS-Policlinico Ospedaliero-Universitario di Bologna, Bologna, Italy

Barry Rodgers-Gray

Violicom Medical Limited, Aldermaston, United Kingdom

John Fullarton

Violicom Medical Limited, Aldermaston, United Kingdom

Xavier Carbonell-Estrany

Neonatology Service, Hospital Clinic, Barcelona, Spain